Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Ltd

₹ 2,025 0.47%
23 May 11:00 a.m.
About

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]

Key Points

Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing

  • Market Cap 1,193 Cr.
  • Current Price 2,025
  • High / Low 2,835 / 1,591
  • Stock P/E 41.0
  • Book Value 434
  • Dividend Yield 0.07 %
  • ROCE 23.2 %
  • ROE 17.0 %
  • Face Value 10.0

Pros

  • Company is almost debt free.
  • Debtor days have improved from 130 to 63.6 days.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Mar 2024 Sep 2024 Mar 2025
29 185 273 348
20 165 252 323
Operating Profit 9 20 20 25
OPM % 32% 11% 8% 7%
2 3 3 3
Interest 0 0 1 1
Depreciation 0 1 0 1
Profit before tax 10 22 22 25
Tax % 25% 15% 16% 19%
6 19 19 21
EPS in Rs 9.58 25.86 23.78 27.17
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
212 620
185 575
Operating Profit 28 46
OPM % 13% 7%
5 5
Interest 0 1
Depreciation 1 2
Profit before tax 32 47
Tax % 18% 19%
26 38
EPS in Rs 36.51 49.34
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 192%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 41%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 7%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
Equity Capital 1 6
Reserves 85 250
12 23
159 154
Total Liabilities 257 433
12 16
CWIP 0 0
Investments 23 186
223 231
Total Assets 257 433

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
4 7
-9 -11
24 6
Net Cash Flow 19 2

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
Debtor Days 197 64
Inventory Days 95 35
Days Payable 208 49
Cash Conversion Cycle 84 50
Working Capital Days 68 65
ROCE % 23%

Shareholding Pattern

Numbers in percentages

Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025
69.61% 70.60% 70.66% 70.84% 70.85%
2.38% 3.25% 3.00% 3.16% 4.77%
0.71% 0.67% 0.73% 0.77% 0.77%
27.30% 25.49% 25.61% 25.22% 23.60%
No. of Shareholders 8561,1241,5771,7531,878

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents